Alzheimer’s disease: natural products as inhibitors of neuroinflammation

Alzheimer’s disease (AD) is the most common form of dementia and affects 44 million people worldwide. New emerging evidence from pre-clinical and clinical investigations shows that neuroinflammation is a major pathological component of AD suggesting that anti-inflammatory strategies are important in...

Full description

Saved in:
Bibliographic Details
Published in:Inflammopharmacology 2020-12, Vol.28 (6), p.1439-1455
Main Authors: Olajide, Olumayokun A., Sarker, Satyajit D.
Format: Article
Language:English
Subjects:
Allergology
Biomedical and Life Sciences
Biomedicine
Dermatology
Gastroenterology
Immunology
Pharmacology/Toxicology
Review
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer’s disease (AD) is the most common form of dementia and affects 44 million people worldwide. New emerging evidence from pre-clinical and clinical investigations shows that neuroinflammation is a major pathological component of AD suggesting that anti-inflammatory strategies are important in delaying the onset or slowing the progression of the disease. However, efforts to employ current anti-inflammatory agents in AD clinical trials have produced limited success. Consequently, there is a need to explore anti-inflammatory natural products, which target neuroinflammatory pathways relevant to AD pathogenesis. This review summarises important druggable molecular targets of neuroinflammation and presents classes of anti-neuroinflammatory natural products with potentials for preventing and reducing symptoms of AD.
ISSN:0925-4692
1568-5608
DOI:10.1007/s10787-020-00751-1